
Alpha Tau Medical rose 224.6% from $3.70 to $12.01, ahead of the S&P 500's +10.6%. Its worst day was May 4 (−11.8%), and its low came Nov 20 at $3.47.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.14 missed the $-0.12 estimate on $0.00 revenue.
+10.1% · S&P 500 +1.0%
Alpha Tau Medical surged in after-hours trading after treating the first patient in its pilot study for recurrent glioblastoma with Alpha DaRT therapy.
Story events cover the past 12 months · Times ET
+19.6% · S&P 500 +0.7%
Alpha Tau Medical shares rose 14.3%, while the S&P 500 fell 0.5%.
+14.3% · S&P 500 −0.5%
EPS of $-0.14 missed the $-0.13 estimate on $0.00 revenue.
+1.9% · S&P 500 −0.2%
Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two patients treated with Alpha DaRT.
+21.5%, the year's best day, on 5M shares, the year's heaviest volume · S&P 500 +0.2%
EPS of $-0.26 missed the $-0.12 estimate on $0.00 revenue (est. $113,600.00).
+6.5% · S&P 500 −0.7%
- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S.
+18.5% · S&P 500 −0.7%
Alpha Tau Medical shares rose 14.1%, while the S&P 500 fell 1.0%.
+14.1% · S&P 500 −1.0%
EPS of $-0.50 missed the $-0.14 estimate on $0.00 revenue (est. $230,136.00).
+4.9% · S&P 500 −0.3%
Alpha Tau Medical closed at its highest level of the year, 318.9% above where the year started.
+1.7% · S&P 500 +1.6%
Where it ended: a close of $12.01 on Nov 18, 2026. Up next: Q3 2026 earnings on Dec 1, 2026 (EPS est. $-0.15, revenue est. $166,670.00).
Nothing in the past 12 months.
All DRTS dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for DRTS and SPY from Benzinga historical bars. Not investment advice.